Evidence map›Paper›PMID 30271848›Full record

ArticleRegenerative therapy2017

Human resource development contributes to the creation of outstanding regenerative medicine products.

Fusako Nishigaki, Sachikon Ezoe, Hideki Kitajima, Kenichiro Hata, Forum for Innovative Regenerative Medicine (FIRM)

Abstract read
In one paragraph

Article in Regenerative therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Comparative study of mesenchymal stem cells from rat bone marrow and adipose tissue.Turkish journal of biology = Turk biyoloji dergisi · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fusako NishigakiRegenerative Medicine Labs., Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan.
Sachikon EzoeDepartment of Medical Innovation, Osaka University Hospital, 2-1, Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Hideki KitajimaDepartment of Medical Innovation, Osaka University Hospital, 2-1, Yamada-Oka, Suita, Osaka, 565-0871, Japan.
Kenichiro HataForum for Innovative Regenerative Medicine (FIRM), 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan.
Forum for Innovative Regenerative Medicine (FIRM)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regenerative medicine is currently the focus of global attention. Countries all around the world are actively working to create new regenerative treatment modalities through pioneering research and novel technologies. This is wonderful news for patients who could not be treated with existing medical options. New venture businesses and companies are being established in regenerative medicine and their rapid industrialization is anticipated. However, to ensure high-quality products, human resources qualified in research and development and the manufacturing of these products are essential. The Forum for Innovative Regenerative Medicine (FIRM) conducted a questionnaire of its industry members to examine the training and hiring of people in research and development, product creation, manufacturing, and more. Regenerative medicine is a brand new field; thus, many different businesses will need to cooperate together. People with a broad range of technical skills, abilities, and knowledge will be in demand, with various levels of expertise, from basic to advanced.

Indexed as

EducationFIRM, Forum for Innovative Regenerative MedicineGCTP, Good Gene, Cellular, and Tissue-based Products Manufacturing PracticeGMP, Good Manufacturing PracticeHuman resourceiPS, induced pluripotent stemRegenerative medicineTraining

Identifiers

PMID30271848
PMCPMC6134916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.